Total Payments
$794.38
2021 Payments
$56.17
Companies
8
Transactions
20
Medicare Patients
1,327
Medicare Billing
$187,125
Payment Breakdown by Category
Food & Beverage$498.56 (62.8%)
Education$295.82 (37.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $498.56 | 16 | 62.8% |
| Education | $295.82 | 4 | 37.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $268.94 | 4 | $0 (2018) |
| Janssen Biotech, Inc. | $249.14 | 5 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $99.00 | 1 | $0 (2020) |
| Astellas Pharma US Inc | $77.09 | 4 | $0 (2019) |
| AbbVie, Inc. | $33.72 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $32.13 | 2 | $0 (2018) |
| PFIZER INC. | $22.44 | 1 | $0 (2021) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $56.17 | 3 | PFIZER INC. ($22.44) |
| 2020 | $141.43 | 3 | Pharmacyclics LLC, An AbbVie Company ($99.00) |
| 2019 | $103.65 | 2 | Janssen Biotech, Inc. ($84.95) |
| 2018 | $438.91 | 9 | Genentech USA, Inc. ($268.94) |
| 2017 | $54.22 | 3 | Novartis Pharmaceuticals Corporation ($20.55) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/28/2021 | PFIZER INC. | XALKORI (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: ONCOLOGY | ||||||
| 07/28/2021 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 08/26/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 05/07/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Oncology | ||||||
| 04/23/2020 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Oncology | ||||||
| 12/30/2019 | Astellas Pharma US Inc | PADCEV (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $84.95 | General |
| Category: Oncology | ||||||
| 10/16/2018 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), SANDOSTATIN LAR | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 09/18/2018 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 08/15/2018 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $8.18 | General |
| Category: BioOncology | ||||||
| 05/16/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Virology | ||||||
| 04/26/2018 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $114.62 | General |
| Category: BioOncology | ||||||
| 03/20/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: BioOncology | ||||||
| 04/18/2017 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Virology | ||||||
| 04/04/2017 | Astellas Pharma US Inc | Tarceva (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: Oncology | ||||||
| 03/09/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 30 | 1,327 | 8,609 | $791,710 | $187,125 |
Total Patients
1,327
Total Services
8,609
Medicare Billing
$187,125
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2020 | 11 | 18 | $302,832 | $58,465 | 19.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 82 | 321 | $51,360 | $50,826 | 99.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 68 | 155 | $106,330 | $18,716 | 17.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 169 | 306 | $45,288 | $17,087 | 37.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 39 | 54 | $12,096 | $4,945 | 40.9% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2020 | 18 | 4,050 | $24,300 | $4,517 | 18.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 22 | $9,064 | $3,699 | 40.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 26 | 26 | $8,918 | $3,206 | 36.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 215 | 394 | $13,790 | $3,023 | 21.9% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 54 | 174 | $24,360 | $2,454 | 10.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 30 | 44 | $13,376 | $2,450 | 18.3% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2020 | 19 | 38 | $12,692 | $2,280 | 18.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 33 | 65 | $7,475 | $2,121 | 28.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 18 | 18 | $5,346 | $2,090 | 39.1% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2020 | 14 | 30 | $6,150 | $2,006 | 32.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2020 | 28 | 520 | $63,440 | $1,934 | 3.0% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 26 | 50 | $7,600 | $1,356 | 17.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 223 | 381 | $7,239 | $1,129 | 15.6% |
| 96411 | Infusion of different chemotherapy drug or substance into a vein | Office | 2020 | 12 | 20 | $5,620 | $1,052 | 18.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 23 | 27 | $2,700 | $1,011 | 37.5% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 20 | 38 | $5,928 | $999.30 | 16.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 28 | 54 | $5,022 | $616.39 | 12.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2020 | 13 | 57 | $26,334 | $506.46 | 1.9% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2020 | 13 | 261 | $11,745 | $333.29 | 2.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 47 | 950 | $950.00 | $94.12 | 9.9% |
About Dr. Amy Irwin, M.D
Dr. Amy Irwin, M.D is a Hematology & Oncology healthcare provider based in Reston, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1063685121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Irwin, M.D has received a total of $794.38 in payments from pharmaceutical and medical device companies, with $56.17 received in 2021. These payments were reported across 20 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($498.56).
As a Medicare-enrolled provider, Irwin has provided services to 1,327 Medicare beneficiaries, totaling 8,609 services with total Medicare billing of $187,125. Data is available for 1 year (2020–2020), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Reston, VA
- Active Since 04/10/2008
- Last Updated 12/23/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063685121
Products in Payments
- IMBRUVICA (Drug) $184.90
- Perjeta (Biological) $143.94
- Imbruvica (Drug) $99.00
- DARZALEX (Biological) $42.87
- XTANDI (Drug) $40.38
- Venclexta (Drug) $33.72
- XALKORI (Drug) $22.44
- ERLEADA (Drug) $21.37
- TASIGNA (Drug) $20.55
- PADCEV (Drug) $18.70
- Tarceva (Drug) $18.01
- AFINITOR (Drug) $11.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.